Merck Cancer Shot Cuts Genital Warts, Lesions in Men
"We finally have something we may be able to offer men as well as women,'' said Anna Giuliano, professor of medicine and epidemiology at the University of South Florida and a program leader in risk assessment at the H. Lee Moffitt Cancer Center in Tampa, Florida. "It really opens the door to preventing infection and hopefully cancer and genital warts in males.''
Nov. 13 (Bloomberg) -- Merck & Co.'s Gardasil shot, used to prevent cervical cancer in women, slashed the risk of genital warts and pre-cancerous lesions by 90 percent in men, according to the largest study of the vaccine in males.
Merck said it will use the data to seek U.S. approval to sell Gardasil for males this year to protect against warts and the lesions, which may lead to cancer of the penis and anus. The shot protects against the sexually transmitted human papillomavirus, or HPV.
Read the rest here.
No comments:
Post a Comment